Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma?

C Mattevi, J Garnier, U Marchese, J Ewald, M Gilabert, F Poizat, G Piana, J R Delpero, O Turrini, C Mattevi, J Garnier, U Marchese, J Ewald, M Gilabert, F Poizat, G Piana, J R Delpero, O Turrini

Abstract

Purpose: To determine if improvement in imaging reduces the non-resection rate (NRR) among patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: From 2000 to 2019, 751 consecutive patients with PDAC were considered eligible for a intention-to-treat pancreatectomy and entered the operating room. In April 2011, our institution acquired a dual energy spectral computed tomography (CT) scanner and liver diffusion weighted magnetic resonance imaging (DW-MRI) was included in the imaging workup. We consequently considered 2 periods of inclusion: period #1 (February 2000-March 2011) and period #2 (April 2011-August 2019).

Results: All patients underwent a preoperative CT scan with a median delay to surgery of 18 days. Liver DW-MRI was performed among 407 patients (54%). Median delay between CT and surgery decreased (21 days to 16 days, P < .01), and liver DW-MRI was significantly most prescribed during period #2 (14% vs 75%, P < .01). According to the intraoperative findings, the overall NRR was 24.5%, and remained stable over the two periods (25% vs 24%, respectively). While vascular invasion, liver metastasis, and carcinomatosis rates remained stable, para-aortic lymph nodes invasion rate (0.4% vs 4.6%; P < 0.001) significantly increased over the 2 periods. The mean size of the bigger extra pancreatic tumor significantly decrease (7.9 mm vs 6.4 mm (P < .01), respectively) when the resection was not done. In multivariate analysis, CA 19-9 < 500 U/mL (P < .01), and liver DW-MRI prescription (P < .01) favoured the resection.

Conclusions: Due to changes in our therapeutic strategies, the NRR did not decrease during two decades despite imaging improvement.

Keywords: CT; Liver MRI; Pancreatic adenocarcinoma; Staging.

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Survival in patients who benefit (1a) or not (1b) from resection according to period of surgery

References

    1. Ducreux M, Cuhna AS, Caramella C et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v56–68.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma (Version 2. 2018).
    1. Lu J, Hu D, Tang H, et al. Assessment of tumor heterogeneity: differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis. Eur J Radiol. 2019;115:1–9.
    1. Traverso LW. What are the problems associated with the surgical treatment of patients with pancreatic cancer? J Hepato-Biliary-Pancreat Surg. 1998;5(2):138–142.
    1. Marion-Audibert AM, Vullierme MP, Ronot M, et al. Routine MRI with DWI sequences to detect liver metastases in patients with potentially Resectable pancreatic ductal carcinoma and Normal liver CT: a prospective multicenter study. AJR Am J Roentgenol. 2018;211(5):W217–W225.
    1. Hayano K, Miura F, Wada K, et al. Diffusion-weighted MR imaging of pancreatic cancer and inflammation: prognostic significance of pancreatic inflammation in pancreatic cancer patients. Pancreatology. 2016;16(1):121–126.
    1. Schwarz L, Lupinacci RM, Svrcek M, et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg. 2014;101(5):530–538.
    1. Marchese U, Ewald J, Gilabert M, Delpero JR, Turrini O. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated Para-aortic lymph node involvement. J Visc Surg. 2019;156(2):97–101.
    1. Al Faraï A, Garnier J, Ewald J, et al. International study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma:the Paoli-Calmettes institute experience. Eur J Surg Oncol. 2019;3.
    1. Wartski M, Sauvanet A. In: 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Wartski M, Sauvanet A, editors. 2019.
    1. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.
    1. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds pathology protocol (LEEPP) HPB (Oxford) 2009;11(1):18–24.
    1. van der Geest LGM, Lemmens VEPP, de Hingh IHJT, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017;104(11):1568–1577.
    1. Du T, Bill KA, Ford J, et al. The diagnosis and staging of pancreatic cancer: a comparison of endoscopic ultrasound and computed tomography with pancreas protocol. Am J Surg. 2018;215(3):472–475.
    1. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American pancreatic association. Radiology. 2014;270(1):248–260.
    1. Healy GM, Redmond CE, Murphy S, et al. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? Abdom Radiol (NY). 2018;43(3):620–628.
    1. Sanjeevi S, Ivanics T, Lundell L, et al. Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. Br J Surg. 2016;103(3):267–275.
    1. Glant JA, Waters JA, House MG et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607–616.
    1. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. Opportunity lost? Diagnostic laparoscopy in patients with pancreatic Cancer in the National Surgical Quality Improvement Program Database. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. World J Surg. 2019;43(3):937–943.
    1. Looijen GA, Pranger BK, de Jong KP, Pennings JP, de Meijer VE, Erdmann JI. The additional value of laparoscopic ultrasound to staging laparoscopy in patients with suspected pancreatic head Cancer. J Gastrointest Surg. 2018;22(7):1186–1192.
    1. Petrushnko W, Gundara JS, De Reuver PR, O'Grady G, Samra JS, Mittal A. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB (Oxford). 2016;18(8):652–663.
    1. Medrano J, Garnier J, Ewald J, et al. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. Pancreatology. 2020;20(2):223–228.
    1. Bowman AW, Bolan CW. MRI evaluation of pancreatic ductal adenocarcinoma: diagnosis, mimics, and staging. Abdom Radiol (NY) 2019;44(3):936–949.
    1. Nagayama Y, Tanoue S, Inoue T, et al. Dual-layer spectral CT improves image quality of multiphasic pancreas CT in patients with pancreatic ductal adenocarcinoma. Eur Radiol. 2019;16.
    1. Ebner M, Patel PA, Atkinson D, et al. Super-resolution for upper abdominal MRI: acquisition and post-processing protocol optimization using brain MRI control data and expert reader validation. Magn Reson Med. 2019;82(5):1905–1919.
    1. Wang S, Shi H, Yang F, Teng X, Jiang B. The value of 18F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer. Abdom Radiol (NY). 2019.
    1. Alberghina N, Sánchez-Montes C, Tuñón C, et al. Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis. Pancreatology. 2017;17(5):858–864.
    1. Newton AD, Predina JD, Shin MH, et al. Intraoperative near-infrared imaging can identify neoplasms and aid in real-time margin assessment during pancreatic resection. Ann Surg. 2019;270(1):12–20.
    1. van Veldhuisen E, Walma MS, van Rijssen LB, et al. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. HPB (Oxford) 2019;S1365-182X(19):30102–30109.
    1. Tao L, Su L, Yuan C, et al. Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer. Cancer Manag Res. 2019;11:7405–7425.
    1. González-Borja I, Viúdez A, Goñi S, et al. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:8.
    1. Chang JC, Kundranda M. Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci. 2017;20:18(3).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する